Understanding Follicular Lymphoma (Part 2) with Dr. Talal Hilal

If you've recently been diagnosed with follicular lymphoma, you're likely grappling with a flurry of emotions and questions about what comes next. Understanding the management of this condition is crucial for making informed decisions about your health.

On April 3rd, 2024, Dr. Talal Hilal, from Mayo Clinic, along with two other lymphoma specialists, joined HealthTree in a virtual roundtable to discuss the basics of follicular lymphoma. You can watch Dr. Hilal’s recording or read the summary.

Dr. Hilal discussed diagnosis, staging, and grading, and what kind of tests are used to diagnose and monitor follicular lymphoma. Below are some key points from his presentation:

• Like many cancers, diagnosing follicular lymphoma starts with a biopsy. This helps determine the extent of lymphoma involvement and whether there's a risk of transformation into a more aggressive subtype.
• About 85% of people with follicular lymphoma have a specific genetic alteration that triggers the lymphoma's development. 
• Based on the number of larger cells seen under the microscope, there are different grades of follicular lymphoma, ranging from 1 to 3B. However, recent studies question the significance of these grades, suggesting that grades 1 through 3A behave similarly in terms of prognosis.
• After diagnosis, staging helps determine the extent of the disease. Surprisingly, advanced-stage disease involving multiple parts of the body is the most common presentation of follicular lymphoma. However, this doesn't necessarily mean it's terminal. Treatment decisions aren't solely based on stage; factors like symptoms and disease volume also influence treatment plans.
• Predicting a patient's prognosis can be challenging. Various models, like the FLIPI score, estimate prognosis based on age, stage, and blood test results. However, these models have limitations and may not accurately predict individual outcomes.
• Treatment decisions consider factors like grade, stage, and patient symptoms. While higher-grade lymphomas may require more aggressive therapy, follicular lymphoma is known for its heterogeneity. Some patients experience quick progression, while others have long-term remissions after treatment.

In summary, diagnosing and treating follicular lymphoma requires a comprehensive approach. While we have tools to guide treatment, predicting outcomes remains challenging, emphasizing the need for close monitoring and personalized treatment plans.

To stay up-to-date and join our next webinar, sign up for our follicular lymphoma newsletter.

SUBSCRIBE TO OUR NEWSLETTER